Nature Communications (Nov 2017)
Combating subclonal evolution of resistant cancer phenotypes
- Samuel W. Brady,
- Jasmine A. McQuerry,
- Yi Qiao,
- Stephen R. Piccolo,
- Gajendra Shrestha,
- David F. Jenkins,
- Ryan M. Layer,
- Brent S. Pedersen,
- Ryan H. Miller,
- Amanda Esch,
- Sara R. Selitsky,
- Joel S. Parker,
- Layla A. Anderson,
- Brian K. Dalley,
- Rachel E. Factor,
- Chakravarthy B. Reddy,
- Jonathan P. Boltax,
- Dean Y. Li,
- Philip J. Moos,
- Joe W. Gray,
- Laura M. Heiser,
- Saundra S. Buys,
- Adam L. Cohen,
- W. Evan Johnson,
- Aaron R. Quinlan,
- Gabor Marth,
- Theresa L. Werner,
- Andrea H. Bild
Affiliations
- Samuel W. Brady
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- Jasmine A. McQuerry
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- Yi Qiao
- Department of Human Genetics, School of Medicine, University of Utah
- Stephen R. Piccolo
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- Gajendra Shrestha
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- David F. Jenkins
- Division of Computational Biomedicine, School of Medicine, Boston University
- Ryan M. Layer
- Department of Human Genetics, School of Medicine, University of Utah
- Brent S. Pedersen
- Department of Human Genetics, School of Medicine, University of Utah
- Ryan H. Miller
- Department of Oncological Sciences, School of Medicine, University of Utah
- Amanda Esch
- Department of Biomedical Engineering, Oregon Health & Science University
- Sara R. Selitsky
- Department of Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina
- Joel S. Parker
- Department of Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina
- Layla A. Anderson
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- Brian K. Dalley
- High-Throughput Genomics and Bioinformatic Analysis, Huntsman Cancer Institute
- Rachel E. Factor
- Department of Pathology, Huntsman Cancer Hospital
- Chakravarthy B. Reddy
- Department of Internal Medicine, Pulmonary Division, School of Medicine, University of Utah
- Jonathan P. Boltax
- Department of Internal Medicine, Pulmonary Division, School of Medicine, University of Utah
- Dean Y. Li
- Department of Oncological Sciences, School of Medicine, University of Utah
- Philip J. Moos
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- Joe W. Gray
- Department of Biomedical Engineering, Oregon Health & Science University
- Laura M. Heiser
- Department of Biomedical Engineering, Oregon Health & Science University
- Saundra S. Buys
- Department of Internal Medicine, Huntsman Cancer Institute, University of Utah
- Adam L. Cohen
- Department of Internal Medicine, Huntsman Cancer Institute, University of Utah
- W. Evan Johnson
- Department of Oncological Sciences, School of Medicine, University of Utah
- Aaron R. Quinlan
- Department of Biomedical Informatics, School of Medicine, University of Utah
- Gabor Marth
- Department of Human Genetics, School of Medicine, University of Utah
- Theresa L. Werner
- Department of Medicine, Oncology Division, Huntsman Cancer Institute, University of Utah
- Andrea H. Bild
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah
- DOI
- https://doi.org/10.1038/s41467-017-01174-3
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
In metastatic breast cancer, subclonal evolution can drive drug resistance. Here, the authors genetically and transcriptionally follow the evolution of four breast cancers over time and treatment, and suggest a phenotype-targeted treatment strategy to adapt to cancer as it evolves.
